Identification and Characterization of Cefazolin-Induced Liver Injury
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background &Aims Cephalosporin antibiotics are popular because they have a broad spectrum of activity and are generally well tolerated; cephalosporin-induced liver injury is considered to be rare. We describe a new syndrome associated with a single intravenous dose of cefazolin and the clinical features of cephalosporin-induced liver injury. Methods The drug-induced liver injury (DILI) network collected detailed clinical data on 1212 patients with DILI between 2004 and 2012. We analyzed data from 41 patients in whom cephalosporins were implicated as primary agents of liver disease; 33 were formally adjudicated as having cephalosporin-induced DILI. Results Nineteen patients developed clinically apparent DILI after a single intravenous dose of cefazolin. All patients developed self-limited liver injury 3–23 days after receiving cefazolin during surgery—often during a minor outpatient procedure. The latency period was 20 days. Clinical features included itching, jaundice, nausea, fever, and rash. We identified 14 more patients with DILI attributed to other cephalosporins (5 first-, 2 second-, 6 third-, and 1 fourth-generation agents). Although latency and injury patterns were similar for cefazolin and other cephalosporins, the other cephalosporins were associated with more severe courses of injury, including 2 deaths from liver failure. Conclusions DILI can develop following a single dose of cefazolin. It is characterized by a latency period of 1–3 weeks after exposure, marked cholestasis, and a self-limited moderate to severe clinical course. Other cephalosporins can cause a similar but more severe injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Cited by
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Self-citationSundaram, V., & Björnsson, E. S. (2017) · Hepatology Communications · doi:10.1002/hep4.1088 · Cited by 138
Drug-induced liver injury: Highlights from a review of the 2015 literature
Sarges, P., Steinberg, J. M., & Lewis, J. H. (2016) · Drug Safety · doi:10.1007/s40264-016-0427-8 · Cited by 74
Value of liver biopsy in the diagnosis of drug-induced liver injury
Ahmad, J., Barnhart, H. X., Bonacini, M., Ghabril, M., Hayashi, P. H., Odin, J. A., Rockey, D. C., Rossi, S., Serrano, J., Tillmann, H. L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.043 · Cited by 71
Self-citationThe Frequency of Drug-Induced Liver Injury Due to Antibiotics Among Hospitalised Patients
Björnsson, R. A., Sigurdsson, S. S., Arnarson, D. T., Logason, E., & Björnsson, E. S. (2025) · Drug Safety · doi:10.1007/s40264-025-01541-w · Cited by 12
Metadata
- Authors
- Alqahtani, S. A., Kleiner, D. E., Ghabril, M., Gu, J., Hoofnagle, J. H., & Rockey, D. C.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 13
- Issue
- 7
- Pages
- 1328-1336.e2
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2152034160
- Cited by
- 61
- References
- 2
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification and Characterization of Cefazolin-Induced Liver Injury. https://app.cochat.ai/papers/10.1016/j.cgh.2014.11.036
- The paper
- Alqahtani, S. A., Kleiner, D. E., Ghabril, M., Gu, J., Hoofnagle, J. H., & Rockey, D. C. (2015). Identification and Characterization of Cefazolin-Induced Liver Injury. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2014.11.036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.